A detailed history of Virtus ETF Advisers LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 6,637 shares of HALO stock, worth $370,145. This represents 0.18% of its overall portfolio holdings.

Number of Shares
6,637
Previous 6,637 -0.0%
Holding current value
$370,145
Previous $347,000 9.22%
% of portfolio
0.18%
Previous 0.18%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$37.81 - $52.4 $114,261 - $158,352
-3,022 Reduced 31.29%
6,637 $347,000
Q1 2024

May 15, 2024

BUY
$33.68 - $41.95 $46,815 - $58,310
1,390 Added 16.81%
9,659 $392,000
Q4 2023

Feb 15, 2024

SELL
$33.32 - $42.1 $32,053 - $40,500
-962 Reduced 10.42%
8,269 $305,000
Q3 2023

Nov 07, 2023

SELL
$36.46 - $44.03 $43,423 - $52,439
-1,191 Reduced 11.43%
9,231 $352,000
Q2 2023

Aug 14, 2023

BUY
$30.28 - $38.74 $156,244 - $199,898
5,160 Added 98.06%
10,422 $375,000
Q1 2023

May 15, 2023

BUY
$32.86 - $55.7 $3,023 - $5,124
92 Added 1.78%
5,262 $200,000
Q4 2022

Feb 14, 2023

SELL
$40.06 - $59.44 $9,213 - $13,671
-230 Reduced 4.26%
5,170 $294,000
Q3 2022

Nov 14, 2022

BUY
$38.53 - $51.78 $2,928 - $3,935
76 Added 1.43%
5,400 $214,000
Q2 2022

Aug 12, 2022

SELL
$37.35 - $48.3 $202,212 - $261,496
-5,414 Reduced 50.42%
5,324 $234,000
Q4 2021

Feb 14, 2022

BUY
$31.82 - $40.75 $5,950 - $7,620
187 Added 1.77%
10,738 $432,000
Q3 2021

Nov 15, 2021

SELL
$38.47 - $46.42 $37,085 - $44,748
-964 Reduced 8.37%
10,551 $429,000
Q2 2021

Aug 10, 2021

SELL
$38.84 - $51.31 $133,570 - $176,455
-3,439 Reduced 23.0%
11,515 $523,000
Q1 2021

May 17, 2021

BUY
$39.51 - $51.45 $16,238 - $21,145
411 Added 2.83%
14,954 $623,000
Q4 2020

Feb 12, 2021

SELL
$25.81 - $43.62 $285,690 - $482,829
-11,069 Reduced 43.22%
14,543 $621,000
Q3 2020

Nov 13, 2020

BUY
$25.74 - $29.63 $55,521 - $63,911
2,157 Added 9.2%
25,612 $673,000
Q2 2020

Aug 05, 2020

SELL
$16.25 - $26.81 $122,541 - $202,174
-7,541 Reduced 24.33%
23,455 $629,000
Q1 2020

May 14, 2020

SELL
$13.9 - $21.83 $36,362 - $57,107
-2,616 Reduced 7.78%
30,996 $558,000
Q4 2019

Feb 13, 2020

SELL
$14.93 - $19.53 $155,779 - $203,776
-10,434 Reduced 23.69%
33,612 $596,000
Q3 2019

Nov 12, 2019

SELL
$15.2 - $17.69 $112,708 - $131,171
-7,415 Reduced 14.41%
44,046 $683,000
Q2 2019

Aug 13, 2019

BUY
$14.75 - $17.26 $9,233 - $10,804
626 Added 1.23%
51,461 $884,000
Q1 2019

May 14, 2019

BUY
$13.94 - $17.58 $151,946 - $191,621
10,900 Added 27.29%
50,835 $818,000
Q4 2018

Feb 05, 2019

SELL
$13.33 - $18.66 $16,849 - $23,586
-1,264 Reduced 3.07%
39,935 $584,000
Q3 2018

Nov 14, 2018

BUY
$16.68 - $18.41 $46,303 - $51,106
2,776 Added 7.22%
41,199 $749,000
Q2 2018

Aug 10, 2018

SELL
$16.87 - $20.3 $124,787 - $150,159
-7,397 Reduced 16.14%
38,423 $648,000
Q1 2018

May 14, 2018

SELL
$17.06 - $21.2 $44,031 - $54,717
-2,581 Reduced 5.33%
45,820 $898,000
Q4 2017

Feb 14, 2018

SELL
$16.75 - $20.8 $501,712 - $623,022
-29,953 Reduced 38.23%
48,401 $981,000
Q2 2017

Aug 14, 2017

BUY
N/A
78,354
78,354 $1 Million

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $7.77B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.